CEL-SCI to Present at 18th Annual BIO CEO & Investor Conference
February 03 2016 - 9:00AM
Business Wire
CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert
Kersten, Chief Executive Officer, will be presenting at the 18th
Annual BIO CEO & Investor Conference on Tuesday, February 9,
2016 at 11:00 a.m. Hosted by the Biotechnology Industry
Organization (BIO), the 18th Annual BIO CEO & Investor
Conference will take place February 8-9 at the Waldorf Astoria in
New York City.
A live audio webcast of the presentation and replay will be
available under the investor relations section of CEL-SCI's website
at www.cel-sci.com/investor_relations.html. The replay of the
presentation will be available approximately 1 hour after the
presentation and is accessible until May 8, 2016.
About the BIO CEO & Investor Conference
Now in its eighteenth year, the BIO CEO & Investor
Conference is the largest investor conference focused on
established and emerging publicly traded and select private biotech
companies. Each year this conference provides a neutral forum where
institutional investors, industry analysts, and senior
biotechnology executives have the opportunity to shape the future
investment landscape of the biotechnology industry.
About CEL-SCI Corporation
CEL-SCI is a Phase 3 immunotherapy company with platform
technologies that can potentially treat a variety of cancers and
viral diseases. We believe that one must activate the immune system
BEFORE radiation and chemotherapy, and even before surgery, to
achieve the best results in the greatest number of patients.
CEL-SCI is conducting a Phase 3 trial in 24 countries of Multikine
(Leukocyte Interleukin Injection) for the treatment of head and
neck cancer, which accounts for about 6% of cancers globally and a
$6 billion market. Almost 700 patients are already enrolled in this
study. CEL-SCI is also testing Multikine with the U.S. Navy in HIV
infected patients with HPV related diseases. CEL-SCI has
development partnerships with Teva Pharmaceuticals, Orient
EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its
own 75,000 sq. ft. manufacturing facility and produces Multikine
for its clinical trials. When fully built out, this facility will
have the capacity to supply about $3 billion worth of Multikine
annually. CEL-SCI is also developing its pre-clinical L.E.A.P.S.
(Ligand Epitope Antigen Presentation System) technology as a
potential vaccine for the treatment of rheumatoid arthritis.
The Company has operations in Vienna, Virginia, and in/near
Baltimore, Maryland.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160203005793/en/
COMPANY CONTACT:CEL-SCI CorporationGavin de Windt,
703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Sep 2023 to Sep 2024